INTERSECT ENT INC (XENT) Stock Price, Quote, News and Overview
NASDAQ:XENT - Nasdaq - US46071F1030 - Common Stock
XENT Quote, Performance and Key Statistics
28.24
0 (0%)
The current stock price of XENT is 28.24 null. In the past month the price increased by 0.89%. In the past year, price increased by 59.91%.
XENT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About XENT
Company Profile
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company is headquartered in Menlo Park, California and currently employs 433 full-time employees. The company went IPO on 2014-07-24. The firm's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company also offers ENT products, such as VenSure and CUBE.
Company Info
INTERSECT ENT INC
1555 Adams Dr
Menlo Park CALIFORNIA 94025 US
CEO: Thomas A. West
Employees: 433
Company Website: http://www.intersectent.com/
Phone: 16506412100.0
INTERSECT ENT INC / XENT FAQ
What is the stock price of INTERSECT ENT INC today?
The current stock price of XENT is 28.24 null.
What is the ticker symbol for INTERSECT ENT INC stock?
The exchange symbol of INTERSECT ENT INC is XENT and it is listed on the Nasdaq exchange.
On which exchange is XENT stock listed?
XENT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INTERSECT ENT INC stock?
7 analysts have analysed XENT and the average price target is 28.82 null. This implies a price increase of 2.04% is expected in the next year compared to the current price of 28.24. Check the INTERSECT ENT INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INTERSECT ENT INC worth?
INTERSECT ENT INC (XENT) has a market capitalization of 954.79M null. This makes XENT a Small Cap stock.
How many employees does INTERSECT ENT INC have?
INTERSECT ENT INC (XENT) currently has 433 employees.
What are the support and resistance levels for INTERSECT ENT INC (XENT) stock?
INTERSECT ENT INC (XENT) has a support level at 28.01 and a resistance level at 28.25. Check the full technical report for a detailed analysis of XENT support and resistance levels.
Is INTERSECT ENT INC (XENT) expected to grow?
The Revenue of INTERSECT ENT INC (XENT) is expected to grow by 14.26% in the next year. Check the estimates tab for more information on the XENT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INTERSECT ENT INC (XENT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XENT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XENT, evaluating the profitability, health, valuation and growth aspects
- INTERSECT ENT INC (XENT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INTERSECT ENT INC (XENT) Sales and EPS estimates to see what analysts future expectations are.
- INTERSECT ENT INC (XENT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INTERSECT ENT INC (XENT) Insider and Institutional Ownership to learn about the owners and their transactions.
- INTERSECT ENT INC (XENT) Stock Chart to make your own analysis
- INTERSECT ENT INC (XENT) Latest news and press-releases to stay up to date.
Does INTERSECT ENT INC (XENT) stock pay dividends?
XENT does not pay a dividend.
When does INTERSECT ENT INC (XENT) report earnings?
INTERSECT ENT INC (XENT) will report earnings on 2022-08-04.
What is the Price/Earnings (PE) ratio of INTERSECT ENT INC (XENT)?
INTERSECT ENT INC (XENT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.03).
XENT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to XENT. When comparing the yearly performance of all stocks, XENT is one of the better performing stocks in the market, outperforming 96.39% of all stocks.
XENT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XENT. XENT may be in some trouble as it scores bad on both profitability and health.
XENT Financial Highlights
Over the last trailing twelve months XENT reported a non-GAAP Earnings per Share(EPS) of -5.03. The EPS decreased by -120.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -161.94% | ||
| ROA | -132.19% | ||
| ROE | N/A | ||
| Debt/Equity | -1.52 |
XENT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to XENT. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 37% and a revenue growth 14.26% for XENT